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Abstract
It is generally assumed that type 2 diabetes increases the risk of cognitive dysfunction in old age. As type 2 diabetes is
frequently diagnosed before the age of 50, diabetes-related cognitive dysfunction may also occur before the age of 50.
Therefore, we investigated the association of type 2 diabetes with cognitive function in people aged 35–82 years. In a cross-
sectional study comprising 4,135 participants of the Prevention of Renal and Vascular ENd-stage Disease study (52% men;
mean age (SD), 55 (12) years) diabetes was defined according to the criteria of the American Diabetes Association. Executive
function was measured with the Ruff Figural Fluency Test (RFFT; worst score, 0 points; best score, 175 points), and memory
was measured with the Visual Association Test (VAT; worst score, 0 points; best score, 12 points). The association of diabetes
with cognitive function was investigated with multiple linear or, if appropriate, logistic regression analysis adjusting for
other cardiovascular risk factors and APOE e4 carriership. Type 2 diabetes was ascertained in 264 individuals (6%). Persons
with diabetes had lower RFFT scores than persons without diabetes: mean (SD), 51 (19) vs. 70 (26) points (p,0.001). The
difference in RFFT score was largest at age 35–44 years (mean difference 32 points; 95% CI, 15 to 49; p,0.001) and gradually
decreased with increasing age. The association of diabetes with RFFT score was not modified by APOE e4 carriership. Similar
results were found for VAT score as outcome measure although these results were only borderline statistically significant
(p#0.10). In conclusion, type 2 diabetes was associated with cognitive dysfunction, especially in young adults. This was
independent of other cardiovascular risk factors and APOE e4 carriership.
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Introduction
The global prevalence of diabetes is expected to rise over the next
twenty years due to population growth, the growth of life
expectancy and the increasing prevalence of obesity and physical
inactivity. It is estimated that the total number of people with
diabetes will increase from 171 million in 2000 to 366 million in
2030 [1]. Diabetes causes microvascular and macrovascular
damage resulting in nephropathy, retinopathy and cardiovascular
disease [2,3]. In addition, chronic hyperglycemia can lead to
microvascular changes in the brain [3], probably leading to brain
atrophy and white matter lesions. In autopsy and imaging studies,
diabetes is associated with cerebral atrophy and cerebrovascular
lesions [4,5]. Therefore, diabetes may be an important causal factor
of cognitive decline and development of dementia in late life.
Several studies have investigated the association of diabetes with
cognitive decline. It was not only shown that diabetes increases the
risk of dementia [6,7] but also accelerates cognitive decline in
older persons without dementia [8]. As diabetes is frequently
diagnosed before the age of 50 years, it is likely that the accelerated
cognitive decline in diabetes already occurs at a relatively young
age [9]. A better understanding of the association of diabetes with
cognitive decline may contribute to early prevention of severe
cognitive dysfunction later in life. However, five large cross-
sectional and longitudinal population-based studies in middle-aged
people showed divergent results [10–14]. This might be due to
several factors such as the relatively low prevalence of diabetes in
young people [11], the drop-out of subjects with diabetes during
longitudinal follow-up [12–14], or the different degree of
adjustment for other cardiovascular risk factors [10–14]. More-
over, it was recently suggested that the effect of diabetes on
cognitive function is possibly modified by APOE e4 carriership in
middle-aged and old people [15,16]. Up till now, however, it is not
clear if APOE e4 carriership has a similar effect in younger persons
with diabetes.
The aim of this study was to investigate the association of type 2
diabetes with cognitive function in a large community-based
sample of people aged 35 years or older. The total sample included
4,135 participants of whom 264 persons had diabetes. In all
persons, we established cognitive performance on executive
function and memory tests, cardiovascular risk factors and APOE
e4 carriership.
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Methods
Study population
The study population included all participants of the third
survey of the Prevention of REnal and Vascular ENd-stage
Disease (PREVEND) cohort (Ntotal = 5,862). The PREVEND
study was designed to investigate prospectively the natural course
of microalbuminuria and its association with renal and cardiovas-
cular diseases in the general population. In brief, during 1997–
1998, all 85,421 inhabitants of the city of Groningen, the
Netherlands, aged 28–75 years were invited to participate in this
study. A total of 40,856 (48%) people responded. Participants were
selected based on their urinary albumin excretion (UAC): 3,395
with UAE ,10 mg/dl and 7,768 with UAE .10 mg/dl. People
with insulin-dependent diabetes were excluded. A total of 8,592
participants completed the baseline survey and were followed over
time. During follow-up, 6,984 participants completed the second
survey in 2001–2003, and 5,862 the third survey in 2003–2006
(80% and 68% of the cohort at baseline, respectively). All surveys
included assessments of demographic, anthropometric and
cardiovascular risk factors, and measurements of hematological
and biochemical parameters. Cognitive function tests for executive
function and memory were introduced at the third survey of the
PREVEND study. Further details of the PREVEND study can be
found in Mahmoodi et al. and Lambers Heersink et al. [17,18].
Ethics Statement
The PREVEND study was approved by the medical ethics
committee of the University Medical Center Groningen, The
Netherlands, and conducted in accordance with the guidelines of
the Helsinki declaration. All participants gave written informed
consent.
Executive Function
Executive function was measured with the Ruff Figural Fluency
Test (RFFT) [19,20]. The RFFT requires the participants to draw
as many designs as possible within a set time limit while avoiding
repetitions of designs [19,20]. The RFFT is generally seen as a
measure of executive function but provides information regarding
different cognitive abilities such as planning strategies, divergent
thinking and the ability to shift between different cognitive tasks
[19,20]. The RFFT is sensitive to changes in cognitive function in
young and old persons [20,21]. The main outcome measure of the
RFFT is the total number of unique designs, which varies from 0
points (worst score) to 175 points (best score).
Memory
table-3-captionMemory was measured with the Visual Associ-
ation Test (VAT) [22]. The VAT is a brief learning task that is
designed to detect (impaired) memory including anterograde
amnesia. The test consists of six drawnings of two interacting
objects. The person is asked to name each object and, later, as a
single object of the two is presented the person is asked to name
the other object. The lowest (worst) score is 0 points, the highest
(best) score is 12 points [22].
Type 2 Diabetes
table-3-captionType 2 diabetes was defined as a fasting glucose
$7.0 mmol/L (126 mg/dl) or a non-fasting glucose
$11.1 mmol/L (200 mg/dl), the use of glucose-lowering medica-
tion or self-reported diabetes in a questionnaire at the third survey
[23]. Plasma glucose was measured by dry chemistry (Eastman
Kodak, Rochester, NY). Data on actual use of glucose-lowering
medication were obtained from the InterAction DataBase (www.
iadb.nl) that comprised pharmacy-dispending data from regional
community pharmacies [24].
APOE genotype
Genotyping of APOE allele status (rs429358 and rs7412) was
performed using polymerase chain reaction (PCR) after DNA
extraction from a whole blood sample [25]. Participants were
categorized as APOE e4 carriers (allele combinations e2/e4 or e3/
e4 or e4/e4) or noncarriers (allele e2/e2 or e2/e3 or e3/e3) [25].
Other measurements
Several demographic and cardiovascular risk factors are
associated with cognitive decline and with diabetes. Data on age,
gender and educational level were obtained from a questionnaire
at baseline. Educational level was divided into four groups
according to the International Standard Classification of Educa-
tion (ISCED): primary school (0 to 8 years of education; ISCED 0-
1), lower secondary education (9 to 12 years of education; ISCED
2), higher secondary education (13 to 15 years of education;
ISCED 3-4), and university ($16 years of education; ISCED 5)
[26]. A history of cardiovascular disease was defined as a prior
cardiac, cerebrovascular or peripheral vascular event requiring
hospitalization (at baseline, data were obtained from a question-
naire and during follow-up until the third survey from the Dutch
national registry of hospital discharge diagnoses). At the third
survey all the cardiovascular risk factors were measured. Smoking
was defined as current smoker based on self-report. Blood pressure
was automatically measured (Dinamap) in a supine position during
ten minutes and reported as the average of the two last
measurements. Fasting blood was drawn for the determination
of total cholesterol, HDL cholesterol and glucose. Non-HDL
cholesterol was calculated as total cholesterol minus HDL
cholesterol. Microalbuminuria was determined by nephelometry
in two consecutive 24-hour urine samples, and defined as
albuminuria $30 mg/24 hours [18].
Statistical analysis
Parametric data are presented as mean and standard deviation
(SD) and nonparametric data as median and interquartile range
(IQR). Differences between groups were tested by the indepen-
dent-samples t-test for parametric data and by Mann-Whitney U
test for nonparametric data. Differences in proportion were tested
by Chi-Square test. Trends in proportion across groups were
tested by Linear-by-Linear Association test.
The association of RFFT score with type 2 diabetes was analyzed
by multiple linear regression analysis. RFFT score (total number of
unique designs) was the dependent variable, type 2 diabetes (yes/no)
was the independent variable. The full regression model also
included the independent variables age, gender, educational level,
BMI, smoking, systolic blood pressure, HDL cholesterol, non-HDL
cholesterol, microalbuminuria and APOE e4 carriership to adjust for
possible confounders. Interaction between diabetes and age was
tested by entering the product term type 2 diabetes x age into the
regression model. Similarly, interaction between diabetes and APOE
e4 carriership was tested by entering type 2 diabetes x APOE e4
carriership into the model. In all regression models, the variables
RFFT score, age, BMI, systolic blood pressure, HDL cholesterol
and non-HDL cholesterol were entered as continuous variables. All
other variables were entered as categorical variables. The level of
statistical significance was set at 0.05.
Similar analyses were performed for VAT score as outcome
measure. Because of its skewed distribution VAT score was
dichotomized at the median into low performance (#10 points)
and high performance ($11 points). The association of VAT
Interaction Age and Type 2 Diabetes on Cognition
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performance with type 2 diabetes was analyzed by logistic
regression analysis. All analyses were performed using IBM SPSS
Statistics 20.0 (IBM, Amonk, NY).
Sensitivity analyses
As a consequence of its design, the participants of the third
survey of the PREVEND study had a somewhat higher prevalence
of microalbuminuria than the general population (10% vs. 8%,
respectively) [18,27]. Because this may influence data analyses, the
multiple linear regression analyses for RFFT score were repeated
in a subset of the PREVEND cohort, the Groningen Random
Sample (N=1,651), which had a similar prevalence of microal-
buminuria (8%) and other cardiovascular risk factors as the
general population [18]. However, the logistic regression analyses
for VAT score were not repeated in the Groningen Random
Sample because the number of participants with type 2 diabetes
and low performance on the VAT was very small in this sample
(N= 22). Additionally, the analyses were repeated after exclusion
of all APOE e2 carriers (allele combinations e2/e2, e2/e3 and e2/
e4) because the APOE e2 allele appears to reduce the risk of
Alzheimer’s disease [28], and the effect of APOE e2/4 genotype on
cognitive function is unclear (N= 3,185).
Results
Study population
Of the 5,862 participants of the third survey, 4,158 participants
completed the RFFT (71%). A total of 1,271 participants (22%)
refused to perform the RFFT and 433 (7%) had incomplete RFFT
data. Of those with a complete RFFT, twenty participants (0.5%)
were excluded because their educational level was not known and
three participants (0.1%) because their age was younger than 35
years and their number too small to form a separate age group.
Thus, the total study population included 4,135 persons. The
mean age (SD) was 55 (12) years, 52% was male and 96% was of
Western-European descent (Table 1).
The total study population included 264 persons with type 2
diabetes (6%). Thirty-seven persons (14%) used insulin, 152
persons (58%) used oral glucose-lowering medication, and 4 (2%)
used a combination of the two. Persons with diabetes were older
and had a lower educational level compared to people without
diabetes (Table 1). Also, persons with diabetes had a higher
prevalence of cardiovascular disease history, hypertension and
microalbuminuria and worse values for most cardiovascular risk
factors. Two persons with diabetes (0.8%) had a glucose value
below 4.00 mmol/L but no symptoms of hypoglycemia.
Participants, who did not perform the RFFT were slightly older
(mean age [SD], 56 [12] vs. 55 [12] years; p,0.001), were more
often women (52% vs. 48%; p,0.001) and had a lower educational
level (p,0.001). There were no statistically significant differences in
the prevalence of diabetes (p=0.48), other cardiovascular risk
factors (p$0.39) or APOE e4 carriership (p=0.11).
RFFT and Type 2 Diabetes
Persons with diabetes had lower RFFT scores than persons
without diabetes: mean (SD), 51 (19) points vs. 70 (26) points,
respectively (p,0.001). However, the difference in RFFT score
between persons with and without diabetes was clearly dependent
on age, since it diminished from 32 points (95% CI, 15 to 49;
p,0.001) in persons aged 35–44 years to 2 points (95% CI, –4 to
8; p=0.60) in persons aged 75 years and older (Figure 1). This was
confirmed by multiple linear regression analysis that did not only
show a statistically significant effect for type 2 diabetes (B-
coefficient [95% CI],–40.27 [–57.20 to –23.35]; p,0.001), but
also for the interaction type 2 diabetes x age (Table 2). The
difference in RFFT scores between persons with and without
diabetes decreased by 0.48 point per one-year increment of age
(Table 2). The negative association of diabetes with RFFT score
and the interaction between diabetes and age were also found after
adjustment for several cardiovascular risk factors. There was no
statistically significant interaction between type 2 diabetes and
APOE e4 carriership: B-coefficient for diabetes –38.03 (95% CI, –
55.93 to –20.12; p,0.001), for APOE e4 carriership, 0.22 (95% CI,
–1.27 to 1.71; p=0.77), and for type 2 diabetes x APOE e4
carriership, 4.12 (95% CI, –1.69 to 9.92; p=0.17).
VAT and Type 2 Diabetes
Similar results were found for the association of VAT score with
type 2 diabetes. VAT scores were obtained in 4,053 persons of
whom 2,425 (59%) had a low performance (Table 1). Overall, the
percentage of persons with low performance was higher in persons
with diabetes than in persons without diabetes: 73% vs. 58%
(p,0.001). In persons without diabetes, the percentage of persons
with low performance gradually increased from 45% in age group
35–44 years to 81% in age group 75 years or older (ptrend,0.001)
(Figure 2). However, in persons with type 2 diabetes, the
percentage of persons with low performance was similar in all
age groups and varied between 69–83% (ptrend = 0.37). Thus, the
difference between persons with and without diabetes in perfor-
mance on the VAT was largest in the youngest age group. The
association of type 2 diabetes with low performance on the VAT as
well as the interaction of type 2 diabetes x age was also found in
logistic regression analysis after adjustment for several cardiovas-
cular risk factors (Table 3). However, the odds ratios were only
borderline statistically significant (p#0.10). There was no statisti-
cally significant effect of APOE e4 carriership or the interaction of
type 2 diabetes x APOE e4 carriership (data not shown).
Sensitivity analyses
Essentially similar results were found if the analyses of the
association of RFFT score with type 2 diabetes were repeated in
the Groningen Random Sample. In the full regression model, the
B-coefficient for type 2 diabetes was –37.90 (95% CI, –69.76 to –
6.05; p=0.02), and for type 2 diabetes x age, 0.50 (95% CI, 0.01 to
0.99; p=0.04). If the analyses were repeated after exclusion of all
APOE e2 carries, the negative association of diabetes with RFFT
score and the interaction between diabetes and age were also
found. Comparable to the analyses in the full study population,
there was no interaction between type 2 diabetes and APOE e4
carriership (p=0.08). This was also found after exclusion of all
APOE e2 carriers (data not shown).
Discussion
In this large community-based sample, type 2 diabetes was
negatively associated with cognitive function, especially executive
function and possibly also memory. This negative association was
especially found in young people as the difference in cognitive
function between persons with and without diabetes decreased
with increasing age. In addition, the association of type 2 diabetes
with cognitive dysfunction was not modified by APOE e4
carriership.
Most importantly, we found that the difference in cognitive
function between persons with and without type 2 diabetes was
largest in young persons and decreased with advancing age. This is
similar to the finding that the difference in life expectancy between
people with and without diabetes is largest in young persons [29].
There are several explanations for this result. First, the onset of
Interaction Age and Type 2 Diabetes on Cognition
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type 2 diabetes may be nine to twelve years prior to the clinical
diagnosis [30]. It is likely that in this preclinical period, untreated
chronic hyperglycemia already causes important and irreversible
microvascular changes in the brain [3,30]. Second, the number of
cardiovascular risk factors significantly increases with age in both
people with and without diabetes [31]. As cardiovascular risk
factors act via shared biological pathways, this probably reduces
the difference in cardiovascular risk between the two groups.
Finally, both people with and without diabetes undergo age-
associated neurodegenerative changes that are caused by other
mechanisms such as, for example, oxidative stress, mitochondrial
dysfunction and protein misfolding [32]. Therefore, it can be
hypothesized that the lack of difference in cognitive function
between persons with and without type 2 diabetes in older age
groups is attributable to the accumulation of different cerebrovas-
cular and neurodegenerative changes with aging. This hypothesis
is further supported by the finding that conventional vascular risk
factors may have a different predictive value in young and old
persons. Several studies have found, for example, that an increase
in cholesterol or Framingham risk score predicts a higher risk of
stroke in young persons but not in very old persons [33,34]. Thus,
the effect of risk factors may change over the life course.
Accordingly, the effect of type 2 diabetes on brain structure and
function may be different in young and old persons.
The results in this study were different from the results in the
Third National Health and Nutrition Examination Survey
(NHANES III) [10]. In NHANES III, type 2 diabetes was not
associated with cognitive function. However, NHANES III
included a large proportion of black and Hispanic participants
[10]. Compared with white people who have the same cardiovas-
cular risk factors, black and Hispanic people have less carotid and
coronary artery calcification [35,36]. So maybe, the association
between diabetes and microvascular changes in the brain, and as a
consequence cognitive function, might also be less clear in young
and middle-aged black and Hispanic people. Our findings
were supported by the Maastricht Aging Study (MAAS) and the
Atherosclerosis Risk in Communities (ARIC) cohort study
although the adjustment for other cardiovascular risk factors
was limited in these studies [11–13]. Clearly, adjustment for
other cardiovascular risk factors is important as these risk
factors are also independently associated with cognitive decline
and share common biological pathways with diabetes [37–39].
Table 1. Characteristics of the study population.
All Type 2 Diabetes
No Yes pa
N (%) 4135 (100) 3871 (100) 264 (100)b N/A
Gender, N (%) ,0.001
Men 2157 (52) 1991 (51) 166 (63)
Women 1978 (48) 1880 (49) 98 (37)
Age (years), mean (SD) 55 (12) 54 (11) 64 (10) ,0.001
Educational level, N (%) ,0.001
Primary school 406 (10) 349 (9) 57 (22)
Lower secondary education 1225 (29) 1120 (29) 105 (40)
Higher secondary education 1108 (27) 1054 (27) 54 (20)
University 1396 (34) 1348 (35) 48 (18)
Cardiovascular disease history, N (%) 296 (7) 250 (7) 46 (17) ,0.001
Cardiovascular risk factors
Smoking, N (%) 979 (24) 926 (24) 53 (20) 0.17
Body Mass Index (kg/m2), mean (SD) 27 (4) 27 (4) 30 (5) ,0.001
Systolic blood pressure (mmHg), mean (SD) 126 (18) 125 (18) 136 (19) ,0.001
Glucose (mmol/L), mean (SD) 4.88 (0.95) 4.72 (0.58) 7.24 (1.82) ,0.001
Total cholesterol (mmol/L), mean (SD) 5.36 (1.06) 5.41 (1.03) 4.69 (1.22) ,0.001
HDL cholesterol (mmol/L), mean (SD) 1.41 (0.38) 1.42 (0.38) 1.17 (0.33) ,0.001
Non-HDL cholesterol (mmol/L), mean (SD) 3.96 (1.03) 3.99 (1.01) 3.51 (1.20) ,0.001
Microalbuminuria, N (%) 600 (15) 498 (13) 102 (39) ,0.001
APOE e4 carriershipc, N (%) 1166 (28) 1089 (28) 77 (29) 0.69
RFFT score (points), mean (SD) 69 (26) 70 (26) 51 (19) ,0.001
VAT score (points)d, median (IQR) 10 (9–11) 10 (9–11) 9 (8–11) ,0.001
Low performance (#10 points), N (%) 2425 (59) 2232 (58) 193 (73) ,0.001
High performance ($11 points), N (%) 1628 (39) 1561 (40) 67 (25)
Abbreviations: RFFT, Ruff Figural Fluency Test; VAT, Visual Association Test; SD, standard deviation; IQR, interquartile range; N/A, not applicable.
ap-values refer to comparisons between persons with and without diabetes.
bPrevalence of type 2 diabetes in total study population was 6% (N= 264).
cIncluding e2/e4, e3/e4 and e4/e4. APOE e4 carriership was unknown for 280 persons of the total study population (7%): with diabetes, 18 (7%) and without diabetes, 262
(7%).
dVAT score was unknown for 82 persons of the total study population (2%): with diabetes, 4 (2%) and without diabetes, 78 (2%).
doi:10.1371/journal.pone.0082991.t001
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This reasoning was also followed in the longitudinal Doetinchem
Cohort Study (DCS) that also found a statistically significant
negative association of type 2 diabetes with global cognitive
function in young and middle-aged people after adjustment for a
large number of well-defined cardiovascular risk factors [14].
Therefore, it is highly likely that type 2 diabetes is associated with
cognitive dysfunction in young and middle-aged people.
Several biological mechanisms may explain the relationship
between type 2 diabetes and cognitive dysfunction. First, diabetes
may accelerate cognitive decline through cerebrovascular disease.
It has been found that type 2 diabetes is associated with more
cerebral infarcts and white matter lesions [5]. As well, diabetes
increases the risk of ischemic stroke two- to fourfold [40]. Second,
hyperinsulinemia due to insulin resistance may modulate amyloid-
b release and degradation [41]. Additionally, insulin inhibits
phophorylation of tau, which leads to an increase in neurofibrillary
tangles [41]. Both amyloid-b neuritic plaques and neurofibrillary
tangles are the major histopathological features of Alzheimer’s
disease [42]. Third, chronic hyperglycemia affects brain tissue
through direct toxic effect on neurons by oxidative stress and
accumulation of advanced glycation end-products (AGEs) [43]. In
addition, chronic hyperglycemia causes microvascular changes as
thickening of capillary basement membrane and endothelial cell
degeneration resulting in angiopathy and reduced cerebral blood
flow [3,43]. It is plausible to assume that these neurodegenerative
and vascular changes are important determinants in the associ-
ation of type 2 diabetes with cognitive dysfunction.
Recently, it was found that the effect of diabetes on cognitive
function may be modified by APOE e4 carriership [16]. However,
this was not confirmed in our study. To some extent, this was an
unexpected result because both APOE e4 carriership and diabetes
are associated with neurodegenerative changes due to amyloid-b
and neurofibrillary tangles and vascular changes due atheroscle-
rosis [3,41,44]. On the other hand, there also was no difference in
cognitive decline between diabetic APOE e4 carriers and
noncarriers in the Cardiovascular Health Study (CHS) and in
the MAAS study [12,15]. Therefore, it is still unclear whether
APOE e4 carriership modifies the association of diabetes with
cognitive dysfunction.
Some limitations of this study have to be noted. First, the lack of
a difference in cognitive function between persons with and
without diabetes at high age could be due to selection bias as older
people with cognitive dysfunction are more likely to refuse study
participation than age peers with normal cognitive function [45].
Figure 1. RFFT score dependent on age and the presence of
type 2 diabetes. For clarity, data are presented as mean and 95%
confidence interval in ten year age groups (data unadjusted for possible
confounders). Abbreviation: RFFT, Ruff Figural Fluency Test.
doi:10.1371/journal.pone.0082991.g001
Table 2. Multiple linear regression analysis of Ruff Figural Fluency Test score on type 2 diabetes and age.
Model 1a Model 2a Model 3a
B 95% CI p B 95% CI p B 95% CI p
Age (years) –0.90 –0.96 to –0.84 ,0.001 –0.92 –0.98 to –0.86 ,0.001 –0.92 –0.99 to –0.85 ,0.001
Gender (women vs. men) 0.09 –1.18 to 1.36 0.89 0.01 –1.25 to 1.28 0.98 –0.78 –2.23 to 0.66 0.29
Educational level (vs. primary school)
Lower secondary education 5.88 3.55 to 8.22 ,0.001 6.01 3.68 to 8.34 ,0.001 5.37 3.00 to 7.74 ,0.001
Higher secondary education 13.68 11.25 to 16.11 ,0.001 13.67 11.25 to 16.10 ,0.001 12.80 10.32 to 15.27 ,0.001
University 24.19 21.80 to 26.58 ,0.001 24.16 21.77 to 26.54 ,0.001 22.55 20.07 to 25.02 ,0.001
Type 2 diabetes (yes vs. no) –6.27 –8.90 to –3.63 ,0.001 –40.27 –57.20 to –23.35 ,0.001 –35.91 –53.01 to –18.80 ,0.001
Type 2 diabetes x age - - - 0.54 0.27 to 0.80 ,0.001 0.48 0.22 to 0.75 ,0.001
BMI (kg/m2) - - - - - - –0.15 –0.31 to 0.01 0.07
Smoker (yes vs. no) - - - - - - –2.88 –4.42 to –1.34 ,0.001
Systolic BP (mmHg) - - - - - - –0.01 –0.06 to 0.03 0.52
HDL cholesterol (mmol/L) - - - - - - 2.31 0.40 to 4.22 0.02
Non-HDL cholesterol (mmol/L) - - - - - - 0.11 –0.53 to 0.74 0.74
Microalbuminuria (yes vs. no) - - - - - - –1.39 –3.32 to 0.53 0.16
Abbreviations: B, unstandardized B-coefficient; CI, confidence interval; Systolic BP, Systolic Blood Pressure.
aFor all models: adjusted R2, 0.37; residual standard deviation, 21.
doi:10.1371/journal.pone.0082991.t002
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This could have led to some self-selection in our study and
consequentially, to an overestimation of cognitive performance in
older persons with type 2 diabetes. However, there were no
differences in demographic characteristics and cardiovascular risk
factors at the third survey between participants with diabetes who
did or did not perform the cognitive tests. Also, there are several
other studies that only found a weak association between diabetes
and cognitive function or dementia [6,7]. Second, although type 2
diabetes was clearly associated with executive function, the
findings on memory were less obvious in our study. Probably,
this can be attributed to differences in test characteristics between
the two cognitive tests that we used. The executive function test
(RFFT) is a sensitive test that does not exhibit a significant floor or
ceiling effect [19–21]. However, the memory test (VAT) may lack
sensitivity to subtle changes in memory in young age groups as it
was specifically developed to detect early Alzheimer’s disease [22].
Alzheimer’s disease usually occurs in older age groups. Third, the
PREVEND cohort is enriched for persons with microalbuminuria
which is associated with cognitive dysfunction [46]. However, the
absolute difference in prevalence of microalbuminuria between the
PREVEND cohort and the general population was small and a
sensitivity analysis in a sample that was representative of the
general population showed similar results. Finally, the cross-
sectional design may be considered as a limitation because it does
not allow determing a causal relationship. Our findings have to be
confirmed in a longitudinal study.
The present study also has several strengths. Our study was based
on a large community-based sample with a wide age-range and
included a large number of young and middle-aged people. Most
importantly, the association of cognitive function with diabetes was
adjusted for a large number of well-defined and well-measured
cardiovascular risk factors as well as APOE e4 carriership.
In conclusion, in this study, type 2 diabetes was negatively
associated with cognitive function, especially executive function
and possibly also memory. This was independent of cardiovascular
risk factors and APOE e4 carriership. The difference in cognitive
function between persons with and without type 2 diabetes was
largest in the youngest persons, who were aged 35–44 years.
Figure 2. Percentage of persons with low performance on the
VAT dependent on age and the presence of type 2 diabetes.
Bars represent 95% confidence intervals. Data unadjusted for possible
confounders. Abbreviation: VAT, Visual Association Test.
doi:10.1371/journal.pone.0082991.g002
Table 3. Logistic regression analysis of low Visual Association Test performance on type 2 diabetes and age.
Model 1a Model 2a Model 3a
OR 95% CI p OR 95% CI p OR 95% CI p
Age (years) 1.04 1.03 to 1.05 ,0.001 1.04 1.03 to 1.05 ,0.001 1.04 1.03 to 1.05 ,0.001
Gender (women vs. men) 0.65 0.57 to 0.74 ,0.001 0.65 0.57 to 0.75 ,0.001 0.70 0.61 to 0.82 ,0.001
Educational level (vs. primary school)
Lower secondary education 0.74 0.57 to 0.97 0.03 0.74 0.56 to 0.96 0.02 0.73 0.56 to 0.96 0.03
Higher secondary education 0.66 0.50 to 0.86 0.002 0.66 0.50 to 0.86 0.002 0.66 0.50 to 0.88 0.004
University 0.47 0.36 to 0.61 ,0.001 0.47 0.36 to 0.61 ,0.001 0.48 0.37 to 0.64 ,0.001
Type 2 diabetes (yes vs. no) 1.19 0.88 to 1.61 0.25 6.30 0.95 to 42.02 0.06 5.85 0.86 to 39.88 0.07
Type 2 diabetes x age - - - 0.97 0.95 to 1.00 0.08 0.98 0.95 to 1.01 0.10
BMI (kg/m2) - - - - - - 1.00 0.98 to 1.02 0.80
Smoker (yes vs. no) - - - - - - 1.01 0.86 to 1.18 0.95
Systolic BP (mmHg) - - - - - - 1.00 1.00 to 1.00 0.93
HDL cholesterol (mmol/L) - - - - - - 0.79 0.65 to 0.97 0.02
Non-HDL cholesterol (mmol/L) - - - - - - 1.06 0.99 to 1.13 0.12
Microalbuminuria (yes vs. no) - - - - - - 0.90 0.74 to 1.11 0.34
Abbreviations: OR, odds ratio; CI, confidence interval; Systolic BP, Systolic Blood Pressure.
aNagelkerke R Square for all models, 0.109.
doi:10.1371/journal.pone.0082991.t003
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